Women's Cancer News
Sep. 17, 2014

Radiation and chemotherapy could fight endometrial cancer recurrence
International Federation of Gynecology and Obstetrics
High-risk endometrial cancer patients could be treated effectively by using radiation therapy and chemotherapy simultaneously. These are the findings of a study published in the International Journal of Radiation Oncology - Biology - Physics, which assesses the efficacy and toxicity of the two forms of therapy when used concurrently in patients with stage three and four endometrial cancer.More

Vote for SGO Bylaws Amendments

Attention Full, Senior, and Associate members who joined SGO before 2009: In order to reach a quorum, SGO needs you to cast your vote for the 2014 SGO Bylaws Amendments by Sept. 30. Eligible voters received an email with voting instructions and link on Aug. 28 and Sept. 16 from noreply@directvote.net. If you have any questions, please contact Candy Taylor at candy.taylor@sgo.org.More

Improved survival of ovarian cancer patients receiving treatment guided by comprehensive tumor profiling
Medical News Today
Data from an ovarian cancer registry presented at the European Society for Gynaecological Oncology (ESGO) annual meeting reinforce comprehensive tumor profiling as a “game changer” for oncologists. The preliminary report from the Caris RegistryTM demonstrated significantly longer post-profiling survival in patients with ovarian, fallopian tube or primary peritoneal cancer who were given treatments that their tumor profile showed were likely to benefit them compared with patients who were treated with drugs that profiling suggested would be less effective. Data revealed that patients whose treatment was guided by tumor profiling had a 46 percent lower risk of death.More

Ovarian cancer metastasis promoted by mesothelial cells
Medical News Today
A new study in the Journal of Clinical Investigation indicates that mesothelial cells actively promote the spread of ovarian cancer. Using a three dimensional culture model of ovarian cancer metastasis, Ernst Lengyel and colleagues at the Unviersity of Chicago found that in the presence of cancer cells, mesothelial cells secrete a protein, fibronectin. Fibronectin attracted ovarian cancer cells and encouraged cancer cell binding. More

Ovarian cancer remains elusive to early diagnosis and successful treatment
Medical Xpress
A population-based study of all ovarian cancer cases diagnosed in Australia in 2005 found a crude five year survival rate of 35 percent. Women with more advanced cancer, who were older or had certain cancer subtypes had a poorer prognosis. Women with early stage cancer had the best prognosis but only 20 percent of ovarian cancers are diagnosed at an early stage. In the study published in the Medical Journal of Australia co-author UWA School of Women's and Infants' Health Professor Yee Leung and his colleagues "emphasized the need for primary and secondary prevention and better treatments for ovarian cancer to improve long-term outcomes.” More

Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid
PLOS ONE
A study published the Sept. 12 issue of the PLOS ONE shows that cervicovaginal fluid (CVF) is an excellent source of protein biomarkers for detection of lower female genital tract pathologies and that alpha-actinin-4 derived from CVF is a promising candidate biomarker for the precancerous state of cervical cancer. The proteome analysis revealed 16 candidate biomarkers of which alpha-actinin-4 (p = 0.001) and pyruvate kinase isozyme M1/M2 (p = 0.014) were most promising. More

Open access to clinical trials data
JAMA
Opinions and empirical data are challenging the assumption that the analysis of a clinical trial is straightforward and that analysis by any other group would obtain the same results. In the current issue of JAMA, researchers report their findings based on a rigorous search of previously published reanalyses of RCTs. Their first surprising and discomforting finding was just how infrequently data reanalysis has occurred in medical research. In addition, about half of the reanalyses differed in statistical or analytic approaches, a third differed in the definitions or measurements of outcomes, and most important, a third led to interpretations and conclusions different than those in the original article.More

HPV vaccine reduces prevalence of targeted and non-targeted HPV types
Medical Xpress
A human papillomavirus (HPV) vaccine used in Australia has reduced the prevalence of vaccine-targeted and non-targeted HPV types, researchers have found in a study published in The Lancet. The vaccine was designed to protect against four types of HPV, including two types that commonly cause genital warts and two that cause the majority of cervical cancers. Researchers compared the incidence of HPV in women before and after the vaccine was introduced, finding a 29 percent incidence prior to introducing the vaccine, which dropped to seven per cent in the post-implementation sample.More

Mythbusters: Complementary and alternative treatments in cancer
Medscape Oncology (Free login required)
Over the past decade, complementary and alternative medicine (CAM) has grown into a multi-billion-dollar industry in the United States, with the use of CAM interventions becoming increasingly popular among cancer patients. Studies estimate that at least half of cancer patients use some type of complementary intervention, though the reported range varies from less than 10 percent to more than 60 percent. The number of patients who seek out alternative therapies is quite low, with experts estimating that the percentage falls in the single digits.More